MTOR and endometrioid adenocarcinoma: Endometrioid carcinoma patients had a high prevalence of concurrent mutations of ARID1A, PTEN and PIK3CA and could therefore be easily identifiable candidates for a combination of inhibitors of PARP and the MTOR pathway.